NCT03794804CompletedNot Applicable
Double-blind, Randomized, Parallel-group, Placebo-controlled Study to Evaluate Efficacy of CMS008618 for Common Cold
Enzymatica AB10 sites in 1 country701 target enrollmentStarted: January 28, 2019Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 701
- Locations
- 10
- Primary Endpoint
- WURSS-21 QoL sub score
Study Overview
Brief Summary
This study evaluates the impact of ColdZyme® Mouth Spray on quality of life during common cold. Half of the participants will receive ColdZyme® Mouth Spray, half will receive a placebo device.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 70 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Men and women
- •Age 18 to 70 years old
- •Increased risk for common cold (at least 3 self-reported occurences of common cold within the last 12 months prior to V1) but generally in good health
- •Readiness to comply with trial procedures, including in particular:
- •Use of IP as recommended
- •Filling in diary
- •Keeping habitual life-style, including diet and physical activity level
- •No use of products that may influence the study outcome (e.g. immune suppressants/immune stimulants including natural health products, analgesics/anti-rheumatics, anti-phlogistics, anti-tussives/expectorants, mouth or throat therapeutics, decongestants, antibiotics, anti-histaminergic drugs, nasal drops/spray) during the study (except for the defined "rescue" treatment)
- •Women of child-bearing potential:
- •Have to agree to use appropriate contraception methods
- •Negative pregnancy testing (beta human chorionic gonadotropin test in urine) at V1
- •Participation is based upon written informed consent by the participant following written and oral information by the investigator regarding nature,
Exclusion Criteria
- •Known allergy or hypersensitivity to the components of the investigational product
- •History and/or presence of clinically significant condition/ disorder (self-reported), which per investigator's judgement could interfere with the results of the study or the safety of the subject, e.g.:
- •Nasal disorder (e.g. polyposis, relevant septal deviation, ulcer etc.) and/or reconstructive surgery
- •Asthma, chronic obstructive lung disease or any other acute/chronic airways disease/disorder (e.g. chronic cough of any origin)
- •Acute psychiatric disorders
- •Any other acute/chronic serious organ or systemic diseases
- •Influenza vaccination within the last 3 months prior to V1 and during the study
- •Regular use of products that may influence the study outcome (e.g. immune suppressants/immune stimulants including natural health products, analgesics/anti-rheumatics, anti-phlogistics, antitussives/ expectorants, mouth or throat therapeutics, decongestants, antibiotics, anti-histaminergic drugs, nasal drops/spray) within the last 4 weeks prior to V1
- •Pregnancy or nursing
- •History of (in the past 12 months prior to V1) or current abuse of drugs, alcohol or medication
- •Participation in the present study of a person living in the same household as the subject
- •Inability to comply with study requirements according to investigator's judgement
- •Participation in another clinical study in the 30 days prior to V1 and during the study
Arms & Interventions
ColdZyme
Active Comparator
ColdZyme® Mouth Spray. The IP should be applied every second hour up to 6 times, with each time 2 sprays (1 dose) per occasion.
The IP use should start when following conditions have been fulfilled:
- Answering "Yes" to either of the questions in the subject daily diary: "Do you think/feel you have a cold?" or "Do you think/feel you are coming down with a cold (might be having the first signs of cold)?" AND
- A Jackson score of at least 1 in the subject's cold diary (mild = present, but not disturbing or irritating) for any symptom except headache
The IP should be used until 2 days after the subject is symptom free (=answering "No" to the question "Do you think that you are still sick with this respiratory infection?" for 2 days in a row), but not longer than 10 days in total.
Intervention: ColdZyme (Device)
Placebo
Placebo Comparator
Water based mouth spray manufactured to be similar to ColdZyme® Mouth Spray. The IP should be applied every second hour up to 6 times, with each time 2 sprays (1 dose) per occasion.
The IP use should start when following conditions have been fulfilled:
- Answering "Yes" to either of the questions in the subject daily diary: "Do you think/feel you have a cold?" or "Do you think/feel you are coming down with a cold (might be having the first signs of cold)?" AND
- A Jackson score of at least 1 in the subject's cold diary (mild = present, but not disturbing or irritating) for any symptom except headache
The IP should be used until 2 days after the subject is symptom free (=answering "No" to the question "Do you think that you are still sick with this respiratory infection?" for 2 days in a row), but not longer than 10 days in total.
Intervention: ColdZyme Placebo (Device)
Outcomes
Primary Outcomes
WURSS-21 QoL sub score
Time Frame: Days 1-8 (day 1 is the first day of symptoms)
The primary endpoint is the AUC of Wisconsin Upper Respiratory Symptom Survey (WURSS-21) Quality of Life composite subscore during first 8 days of symptoms, to be assessed in comparison between verum and placebo.
Secondary Outcomes
- 1. Composite daily severity of all symptoms within the Jackson score(Days 1-8 (day 1 is the first day of symptoms))
- AUC days 1-8 composite daily severity of all local symptoms within the Jackson score (mean of morning and evening)(Days 1-8 (day 1 is the first day of symptoms))
- 2. Exposure to any concomitant treatment (including natural health products) that may affect common cold symptoms(Days 1-4 (day 1 is the first day of symptoms))
- Other secondary endpoints: AUC days 1-8 for each single WURSS-21 QoL subscore item(Days 1-8 (day 1 is the first day of symptoms))
- Assessment of symptom sore throat per Sore Throat Scale(Days 1-8)
- Percentage of subjects with confirmed common cold at Visit 2(1-3 days after symptom start)
- Global evaluation of efficacy by subjects and investigators at study end(From enrolment through study completion, maximum 16 weeks)
- AUC days 1-8 composite daily severity of each individual symptom of the Jackson score (mean of morning and evening)(Days 1-8 (day 1 is the first day of symptoms))
- Assessment of symptom intensity(Days 1-4)
- Frequency of subjects with use of concomitant treatment that may affect common cold symptoms or any medication/treatment known to affect common cold symptoms - at any dose(Days 1-4)
- Assessment of duration of first intense phase(From enrolment through study completion, maximum 16 weeks)
Investigators
Study Sites (10)
Loading locations...
Similar Trials
Completed
Not Applicable
Evaluation of ColdZyme® on Experimentally Induced Common Cold.Common ColdNCT02479750Enzymatica AB88
Unknown
Phase 3
Effectiveness and Safety of the of Guaifenesin, Doxylamine Succinate and Hydrochloride Etafedrine Syrup in Improvement of Symptoms Resulting From Acute Respiratory Infections.Upper Airway InfectionsNCT00857987Azidus Brasil174
Completed
Not Applicable
Evaluation of ColdZyme® Mouth Spray on Prevention and Alleviation of Rhinovirus Induced Common ColdCommon ColdNCT02522949Enzymatica AB46
Completed
Phase 1
Efficacy of Homeopathic Nasal Formulation for Management of Experimental Rhinoviral ColdsCommon ColdNCT00358774University of Wisconsin, Madison40
Unknown
Phase 4
Bromelin, a Compound Prepared With Ananas Comocus Extract and Honey, for Acute CoughCough, AcuteNCT01356693Universidade Federal de Pernambuco102